how much of what we believe about mechanism actually comes from appetite threads
how much of what we believe about mechanism actually comes from appetite threads — that is what I am asking, and I have already read the wiki twice.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.
Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.
Does the effect persist with continued dosing or does tolerance develop?
GIP is the arm people argue about because the biology is genuinely unsettled
That conflates receptor affinity with clinical potency. They are related and they are not the same thing.
Why mechanism talk keeps misleading people, including me.
A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.
The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.
Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
Same view. Tolerance developing to the gastric effect while the appetite effect persists explains most of what the side-effect board reports.
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
mechanism explains a direction, not a magnitude
Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.
albumin binding is most of the half-life story
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
Is that from a human study or a preclinical model?
Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.